SCHEMBL1784445

SCHEMBL1784445

CC(C)c1ccc(-c2nn(NC(=O)Cc3cc(F)cc(F)c3)c(=O)c3ccccc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.43
▸ KMT2A Q03164 3/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ ATM Q13315 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ MCHR1 Q99705 1/20 0.40
▸ TP53 P04637 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CTDSP1 Q9GZU7 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ CACNA1H O95180 3/20 0.39
▸ PSEN1 P49768 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30796371 1.00 LMNA (0.43) LMNAKMT2ANPSR1MEN1ATM
SCHEMBL1785673 0.90 MAPT (0.49) LMNAKMT2ANPSR1MEN1MAPT
SCHEMBL30795077 0.90 MAPT (0.49) LMNAKMT2ANPSR1MEN1MAPT
SCHEMBL1789436 0.89 RAB9A (0.50) KMT2ANPSR1MEN1ATMMAPT
SCHEMBL1789074 0.89 LMNA (0.47) LMNAKMT2ANPSR1MEN1MAPT
SCHEMBL30795119 0.89 RAB9A (0.50) KMT2ANPSR1MEN1ATMMAPT
SCHEMBL30794712 0.89 LMNA (0.47) LMNAKMT2ANPSR1MEN1MAPT
SCHEMBL30796353 0.89 MAPT (0.50) LMNAKMT2ANPSR1MEN1MAPT
SCHEMBL1787537 0.89 MAPT (0.50) LMNAKMT2ANPSR1MEN1MAPT
SCHEMBL30796013 0.86 ALDH1A1 (0.51) LMNAKMT2ANPSR1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629143-B2 Potassium channel modulators ABBVIE INC. (US) 2014-01-14 — — US claimed
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-05-26 — — US claimed
US-8629143-B2 Potassium channel modulators ABBVIE INC. (US) 2014-01-14 — — US disclosed
EP-2504317-A1 POTASSIUM CHANNEL MODULATORS Abbott Laboratories (US) 2012-10-03 — — EP disclosed
WO-2011066168-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-06-03 — — WO disclosed
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNQ3 LMNA 1106/4885KMT2A 474/4885NPSR1 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback